Intellia Therapeutics, Inc.

NASDAQ:NTLA

Biotechnology

Healthcare
$9.52 +0.14%

+$0.02 today

Market cap
$1.34B
Beta
1.81
P/E (TTM)
-4.6
EPS (TTM)
-$3.33
52W Low $7.95High $28.25

Volume 9.96M

Average 6.11M

Income Statement

Follow revenue through to earnings.

Revenue

$67.67M

FY 2025 · Annual

+16.9% YoY

Operating Income

-$440.99M

FY 2025 · Annual

Net Income

-$412.69M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue33.05M52.12M36.28M57.88M67.67M
Cost of Revenue6.89M7.57M8.98M10.29M15.92M
Gross Profit26.16M44.55M27.3M47.59M51.75M
Gross Margin79.2%85.5%75.3%82.2%76.5%
Research & Development229.81M419.98M435.07M466.31M388.86M
Selling, General & Admin71.1M90.31M116.5M125.83M119.8M
Operating Expenses294.01M502.71M542.59M581.86M492.74M
Depreciation & Amortization6.89M7.57M8.98M10.29M15.92M
EBITDA(261M)(466.61M)(472.22M)(508.74M)(396.77M)
EBITDA Margin-789.6%-895.3%-1301.8%-879.0%-586.3%
Operating Income(267.85M)(458.16M)(515.29M)(534.26M)(440.99M)
Operating Margin-810.4%-879.0%-1420.5%-923.1%-651.7%
Interest Income1.28M8.54M49.83M47.81M29.2M
Interest Expense00000
Other Income / Expenses(42K)(16.02M)34.1M15.24M28.3M
Income Before Tax(267.89M)(474.19M)(481.19M)(519.02M)(412.69M)
Pre-Tax Margin-810.5%-909.8%-1326.5%-896.8%-609.9%
Income Tax Expense00000
Net Income(267.89M)(474.19M)(481.19M)(519.02M)(412.69M)
Net Margin-810.5%-909.8%-1326.5%-896.8%-609.9%
EPS (Basic)(3.78)(6.16)(5.42)(5.25)(3.81)
EPS (Diluted)(3.78)(6.16)(5.42)(5.25)(3.81)
Weighted Avg Shares70.89M76.97M88.77M98.85M108.38M
Weighted Avg Shares (Diluted)70.89M76.97M88.77M98.85M108.38M

NTLA Earnings Waterfall · TTM

NASDAQ:NTLA · Revenue to Net Income

Key Ratios

EPS$-3.54
Gross Margin-194.7%
Net Margin-625.4%
P/E Ratio-3.4
P/S Ratio87.4

Analysis

$66.1M of revenue converted into -$394.6M of net income for the selected period. Gross margin is -194.7% and net margin is -625.4%, showing how much revenue survives after costs and taxes. EPS is $-3.54, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-K/A8-K/A filingNov 13, 2026
8-KCurrent reportNov 12, 2026
SC 13GSC 13G filingNov 10, 2026
10-QQuarterly reportNov 5, 2026
8-KCurrent reportNov 5, 2026

How much revenue does NTLA generate?

Intellia Therapeutics, Inc. (NTLA) reported $67.67M of revenue in fiscal 2025.

Is NTLA profitable?

Intellia Therapeutics, Inc. (NTLA) reported -$412.69M of net income, with a net margin of -609.9%.